How to use molotinib/mometinib

Molotinib (Ojjaara) is a drug specifically designed to treat moderate or high-risk myelofibrosis (MF). It is suitable for patients with primary and secondary MF, including cases caused by polycythemia vera (PV) and essential thrombocythemia (ET). The drug has been designated as an orphan drug by the U.S. Food and Drug Administration (FDA) and has special clinical significance for the above uses.

Patients should undergo a thorough evaluation before starting molotinib and have relevant blood tests performed periodically during treatment. These tests mainly include platelet complete blood count (CBC) and liver function tests to monitor the effects of the drug on the body and possible adverse reactions. In order to ensure safe and effective treatment, doctors will make necessary adjustments based on the patient's specific situation.

Molotinib is available as an oral tablet with a recommended starting dose of 200 mg once daily. Patients may choose to take the drug before or after meals, but should follow their doctor's prescribing information regardless. During the medication process, patients need to pay close attention to the body's reaction, especially adverse reactions to the medication. If discomfort occurs, you need to communicate with your doctor in time and adjust the dose if necessary. For patients with obvious adverse reactions, especially those with poor tolerance, it is recommended to consider discontinuing molotinib under the guidance of a doctor.

For patients with severe hepatic impairment (Child-Pugh class C), the recommended starting dose is 150 mg once daily. For patients with relatively mild or moderate hepatic impairment, no dose adjustment is recommended. This is because changes in liver function may affect drug metabolism and clearance and require caution. During the period of medication, patients should actively cooperate with the doctor's guidance and conduct necessary examinations regularly.